FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer by Caparello, Chiara et al.
FOLFIRINOX and translational studies: Towards 
personalized therapy in pancreatic cancer
Chiara Caparello, Laura L Meijer, Ingrid Garajova, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, 
Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti 
Chiara Caparello, Alfredo Falcone, Niccola Funel, Enrico 
Vasile, Elisa Giovannetti, University Hospital of Pisa, 56124 
Pisa, Italy
Laura L Meijer, Ingrid Garajova, Tessa Y Le Large, Godefridus 
J Peters, Elisa Giovannetti, Department of Medical Oncology, 
VU University Medical Center, 1081 HV Amsterdam, The 
Netherlands
Laura L Meijer, Tessa Y Le Large, Geert Kazemier, Department 
of Surgery, VU University Medical Center, 1081 HV Amsterdam, 
The Netherlands
Ingrid Garajova, Department of Experimental, Diagnostic and 
Speciality Medicine, University of Bologna, Sant’Orsola-Malpighi 
Hospital, Via Massarenti 9, 40138 Bologna, Italy
Niccola Funel, Elisa Giovannetti, Cancer Pharmacology Lab, 
AIRC Start-Up Unit, University of Pisa, 56124 Pisa, Italy
 
Niccola Funel, Elisa Giovannetti, CNR-Nano, Institute of 
Nanoscience and Nanotechnology, University of Pisa, 56124 
Pisa, Italy
Author contributions: Caparello C, Meijer LL, Garajova I 
and Giovannetti E performed the literature research; Caparello 
C, Meijer LL and Giovannetti E wrote the paper; Le Large TY, 
Funel N and Falcone A reviewed the paper; Vasile E, Peters GJ 
and Kazemier G supervised the project. 
Supported by AIRC/Start-Up (to Giovannetti E); Istituto 
Toscano Tumori ITT-2011 (to Caparello C, Funel N, Vasile E 
and Giovannetti E), Regione Toscana “Fas Salute” (to Funel 
N and Giovannetti E), Bennink Foundation (to Meijer LL, Le 
Large TY, Giovannetti E and Kazemier G), CCA Foundation (to 
Giovannetti E).
Conflict-of-interest statement: The authors have no conflict of 
interest to declare. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Dr. Elisa Giovannetti, Cancer Pharmacology 
Lab, AIRC Start-Up Unit, University of Pisa, via Paradisa, 2, 
56124 Pisa, Italy. elisa.giovannetti@gmail.com
Telephone: +39-05-0996817
Fax: +39-05-0501095
Received: April 29, 2016
Peer-review started: May 2, 2016
First decision: May 30, 2016
Revised: June 9, 2016
Accepted: July 6, 2016 
Article in press: July 6, 2016
Published online: August 21, 2016
Abstract
Pancreatic cancer is an extremely aggressive disease; 
although progress has been made in the last few 
years, the prognosis of these patients remains dismal. 
FOLFIRINOX is now considered a standard treatment 
in first-line setting, since it demonstrated an improved 
overall and progression-free survival vs  gemcitabine 
alone. However, the enthusiasm over the benefit of 
this three-drug regimen is tempered by the associated 
increased toxicity profile, and many efforts have been 
made to improve the feasibility of this schedule. After 
a more recent phase Ⅲ trial showing an improved 
outcome over gemcitabine, the combination of gemci-
tabine/nab-paclitaxel emerged as another standard 
first-line treatment. However, this treatment is also 
associated with more side effects. In addition, despite 
initial promising data on the predictive role of SPARC 
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inter- and intra-tumor genetic and microenvironmental 
heterogeneity. Immunotherapy showed encouraging 
results in preclinical models, but often failed to 
demonstrate clear benefits in clinical trials for pancreatic 
cancer patients[2]. In a phase Ⅰ study the CD40 agonist 
CP870893, was well tolerated in combination with 
gemcitabine, with 4 partial responses achieved among 
the 22 patients treated, warranting future phase Ⅱ 
trials[3]. Similarly, the combination of chemotherapy and 
immunotherapy using two granulocyte macrophage 
colony-stimulating factor-secreting pancreatic cancer 
cell lines (CG8020/CG2505) alone or in sequence with 
cyclophosphamide showed minimal treatment-related 
toxicity associated with antitumor activity[4]. More 
recently, a trial on prime/boost vaccination with GVAX 
and CRS-207 showed a significantly longer survival (2.2 
mo) compared with Cy/GVAX alone in patients with 
metastatic pancreatic cancer[5]. These results, showing 
a synergistic interaction between effects mediated 
by chemotherapy and the immune system, raise the 
question as to whether the success of FOLFIRINOX is 
potentially related to the combination of chemotherapy 
with additional, although not intentionally given 
for this purpose, immune modulation via G-CSF, 
which is administered to prevent neutropenia. These 
observations should guide further studies to investigate 
the right combination of immunotherapies and 
chemotherapy. 
However, up to now the standard therapeutic 
approach in pancreatic cancer is represented by 
chemotherapy alone, and new biomarkers to optimize 
treatment selection are urgently warranted. The 
present review summarizes the main therapeutic 
options for pancreatic cancer, mostly focusing on 
recent regimens that represent the new standards in 
metastatic disease. Moreover, we describe biomarkers 
that have been reported to predict drug activity 
in pancreatic cancer, as well as novel potential 
biomarkers, such as microRNA (miRNA).
STANDARD TREATMENTS AND 
PERSPECTIVES FOR PERSONALIZED 
CHEMOTHERAPY
Gemcitabine and gemcitabine-based regimens
Until a few years ago, gemcitabine was considered as a 
standard of treatment for metastatic pancreatic cancer 
as it seemed to be more effective in clinical benefit 
than 5-fluorouracil (5-FU)[6]. However, the median 
OS with gemcitabine was 5.65 mo with a probability 
of surviving beyond 12 mo of 18% and a very low 
response rate of 5.4%. 
Many attempts have been made in order to evaluate 
gemcitabine-based combinations: the combination 
of gemcitabine and capecitabine seemed to improve 
response rate and progression free survival (PFS) vs 
gemcitabine alone, but showed only a trend towards 
improved OS. Only the meta-analysis of two additional 
Caparello C et al . FOLFOXIRINOX, new treatments and translational studies
6988 August 21, 2016|Volume 22|Issue 31|WJG|www.wjgnet.com
levels, recent studies showed that these levels are not 
associated with nab-paclitaxel efficacy. The choice to 
use this treatment over FOLFIRINOX is therefore a 
topic of debate, also because no validated biomarkers 
to guide FOLFIRINOX treatment are available. In the 
era of actionable mutations and target agents it would 
be desirable to identify molecular factors or biomarkers 
to predict response to therapy in order to maximize the 
efficacy of treatment and avoid useless toxic effects 
for non-responding patients. However, until today the 
milestone of treatment for pancreatic cancer remains 
chemotherapy combinations, without predictive or 
monitoring tools existing to optimize therapy. This 
review analyzes the state-of-the-art treatments, promises 
and limitations of targeted therapies, ongoing trials 
and future perspectives, including potential role of 
microRNAs as predictive biomarkers.
Key words: FOLFIRINOX; Personalized therapy; New 
treatments; MicroRNA; Pancreatic cancer
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Core tip: The present manuscript is a review of the 
state of the art treatments, focusing on biomarkers, 
target therapies and future perspectives in order to 
develop personalized treatments.
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INTRODUCTION
Pancreatic cancer is estimated to be the fourth leading 
cause of cancer-related death in the United States in 
both sexes; the prognosis in these patients is dismal 
with a 5-year relative survival rate of only 7%[1]. 
Because of nonspecific symptoms and its ag-
gressive biological behavior, pancreatic cancer often 
presents as a locally advanced or metastatic disease. 
Some progress has been made in the last few 
years leading to a longer overall survival (OS) in 
metastatic patients undergoing first-line chemotherapy 
treatment, although not all patients will benefit from 
this intense therapy. Currently, no predictive factors of 
response exist. Furthermore no genetic alterations in 
pancreatic cancer have been found that can be tackled 
with targeted therapy. Multiple targeted agents have 
been registered or are under promising clinical trials 
for several tumor types, but similar success has not 
occurred in pancreatic cancer. This therapeutic failure 
can be attributed to several causes, including a strong 
studies involving 935 patients showed a significantly 
improved survival[7]. Similarly, the combination of 
cisplatin and gemcitabine demonstrated a prolonged 
OS and PFS over gemcitabine alone, but not in a 
statistically significant measure[8]. The most recent 
meta-analysis, including 26 studies and 8808 patients, 
confirmed this result and showed only a trend and no 
statistically significant differences when comparing all 
the combinations with fluoropyrimidine and platinum 
compounds to gemcitabine monotherapy[9].
Of note, the EGFR tyrosine kinase inhibitor erlotinib 
showed a slightly increased OS and PFS when it was 
tested in combination with gemcitabine in a phase Ⅲ 
study on 569 patients with unresectable pancreatic 
cancer[10]. The advantage, although statistically 
significant, was clinically not significant enough to 
change the clinical practice. Although skin rash was 
initially proposed as a surrogate marker of efficacy, 
it failed to identify patients with clinical benefit in 
a randomized phase Ⅱ dose-escalation trial[11]. 
Therefore no predictive factor has yet been found to 
be related to the clinical response to erlotinib.
Several studies evaluated potential predictive 
factors of response to gemcitabine (Figure 1A). 
Because of its hydrophilic nature, gemcitabine does 
not cross the cellular membrane by diffusion, and it is 
transported by membrane nucleoside transporters[12]. 
After uptake in the tumor cells, gemcitabine is 
phosphorylated to its active diphosphate (dFdCDP) 
and triphosphate (dFdCTP) metabolites, which inhibit 
the enzyme ribonucleotide reductase (RR) and DNA 
synthesis, respectively[13]. 
The enzyme deoxycytidine kinase (dCK) catalyzes 
the rate-limiting step in the biotransformation of gem-
citabine in its active phosphorylated form gemcitabine 
triphosphate (dFdCTP). Several studies have suggested 
that dCK plays a key role in gemcitabine activity, 
because its deficiency is critically involved in acquired 
resistance in different in vitro models[14,15]. Moreover, 
pretreatment dCK expression and activity levels could 
be used to predict tumor sensitivity; as observed 
with a clear correlation between dCK activity and 
gemcitabine sensitivity in tumor xenografts[16]. How-
ever, the fact that the transfection of the dCK gene 
in kinase-deficient cells only partially overcomes the 
resistance, suggesting the presence of additional 
mechanisms of resistance[17]. Clinically, low tumor dCK 
expression levels were associated with a significantly 
shorter OS and PFS in advanced pancreatic cancer 
patients treated with gemcitabine[18], but this evidence 
is limited by the small number of patients and failure 
to perform multivariate analysis.
Since dCK is saturated at relatively low gemcitabine 
levels and in vitro sensitivity to gemcitabine is most 
optimal at prolonged exposure to low drug levels in the 
nanomolar range[19], it was reasoned that prolonged 
infusion of gemcitabine would be advantageous. 
The fixed dose rate of 10 mg/m2/min infusion of 
gemcitabine gives this pharmacodynamic advantage, 
resulting in the optimal intracellular accumulation 
of dFdCTP, and several phase Ⅰ trials evaluated 
the possibility to prolong the infusion duration[20-22]. 
Remarkably, a randomized phase Ⅱ trial demonstrated 
that prolonged infusion at 10 mg/m2/min, compared 
to the standard dosing regimen, was associated with 
a significant increase in response rate and a trend for 
increased survival in metastatic pancreatic cancer[23]. 
However, this pharmacological advantage failed to 
translate into a survival advantage in the succeeding 
phase Ⅲ study[24].
The most studied biomarker for gemcitabine 
activity in pancreatic cancer is the human equilibrative 
nucleoside transporter 1 (hENT1), which has been 
correlated to in gemcitabine responsiveness in both 
in vitro and in in vivo models of pancreatic cancer. 
Several clinical studies in patients with pancreatic 
6989 August 21, 2016|Volume 22|Issue 31|WJG|www.wjgnet.com
Gemcitabine
Gemcitabine
hENT-1
dCK
dFdCDP
dFdCTP
CYP2C8 Paclitaxel
TUBB3
Paclitaxel
NAB
SPARC
SPARC
SPARC
SPARC
SPARC
SPARC
SPARC
SPARC
Platinum
DNA damage
5'
3'
3'
5'
ERCC1 repair
5'
3'
3'
5'
Irinotecan
CES-2 SN-38
TOP-1
5'
3'
3'
5'
DNA synthesis
TS
5-FdUMP
5-FUdR
5-fluorouracil
DPD DHFU 5-fluorouracil
A B
Figure 1  Candidate biomarkers in the mechanism of action and metabolism of the drugs in the Nab-paclitaxel/gemcitabine (A) and FOLFIRINOX (B) regimens.
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response. Median time to progression was 8.2 mo 
and median OS was 10.2 mo[33]. This regimen was 
further investigated in a phase Ⅲ trial enrolling 
patients with metastatic pancreatic cancer, who were 
randomly assigned to receive FOLFIRINOX regimen or 
gemcitabine monotherapy. This randomized controlled 
trial consisting of 342 patients demonstrated an 
increased OS (11.1 mo vs 6.8 mo, P < 0.001) and PFS 
(6.4 mo vs 3.3 mo, P < 0.001) in favor of FOLFIRINOX, 
with an objective response rate of 31.6%. According 
to EORTC QLQ-C30, the quality of life was similar in 
both arms, but the time to deterioration of quality of 
life was significantly longer in FOLFIRINOX group for 
almost all domains. Unfortunately, FOLFIRINOX has 
shown a severe grade 3-4 toxicity profile with 45.7% 
of neutropenia, 5.4% of febrile neutropenia, 9.1% of 
thrombocytopenia, 14.5% of vomiting and 12.7% of 
diarrhea[34].
The doubts arising about the tolerability of 
FOLFIRINOX regimen prompted a review of the clinical 
data concerning the use of this regimen outside 
clinical trials[35]. Many attempts have been made in 
order to reduce the toxic effects, mostly related to the 
presence of a bolus of 5-FU. A modified FOLFIRINOX 
schedule has been used with concomitant prophylactic 
pegfilgrastim on 60 patients, showing a decrease of 
the incidence of grade 3-4 neutropenia to 3%, with a 
satisfactory response rate of about 30%[36]. The toxic 
effects decreased as well by lowering the starting dose 
of FOLFIRINOX to 80% and using the granulocyte 
growth factor. The efficacy of treatment was similar 
to the original schedule: 40% of the patients with 
metastatic disease achieved partial response[37]. 
FOLFORIXI is a similar schedule with minimal 
adjustments that was developed for colorectal cancer. 
FOLFORIXI does not include the 5-FU bolus, while it 
includes a higher dose of 5-FU continuous infusion and 
a slightly lower dose of irinotecan[38-40]. The FOLFOXIRI 
regimen (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, 
leucovorin 200 mg/m2 followed by fluorouracil 3200 
mg/m2 as a 48-h continuous infusion) and a modified 
schedule (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, 
leucovorin 200 mg/m2 followed by 5-FU 2800 mg/m2 
as a 48-h continuous infusion) were recently used 
in 137 stage Ⅲ and Ⅳ pancreatic cancer patients. 
One complete response (0.6%) and 52 (38%) 
partial responses were observed in the whole study 
population, with a disease control rate of 72.2%, 
median OS was 12 mo in the entire study population 
and median PFS 8 mo. The toxicity profile was 
manageable: the main hematologic grade 3-4 toxicity 
was neutropenia (35.7%), but only one patient (0.7%) 
experienced febrile neutropenia. The main grade 
3-4 non-hematological adverse events were grade 3 
diarrhea in 11 (8%), nausea in 10 (7.3%), stomatitis 
in 9 (6.5%) and liver toxicity in 6 (4.4%) patients[41]. 
Several clinical prognostic factors have been 
identified in the FOLFIRINOX phase Ⅲ trial: in the 
carcinoma treated with gemcitabine demonstrated 
that the overexpression of hENT1 mRNA and protein 
correlated with significantly longer survival[25-27]. 
Furthermore the retrospective analysis of the phase 
Ⅲ trials RTOG-9704 and ESPAC-1/3 demonstrated its 
role as a predictive biomarker of adjuvant gemcitabine 
efficacy: OS was significantly longer in patients treated 
with gemcitabine with high-hENT1 expression vs low-
hENT1 expression. Importantly, these results were not 
seen in patients treated with 5-FU[27,28], suggesting a 
predictive more than prognostic role. 
However, the first biomarker stratified trial (LEAP) 
with prospective analysis of hENT1 expression 
comparing gemcitabine vs its lipophilic analog CO-101 
failed to demonstrate this correlation in metastatic 
disease[29]. In addition, immunohistochemistry analysis 
of the expression of hENT1 with the rabbit monoclonal 
antibody SP120 in patients’ tumor samples from the 
CONKO-001 phase Ⅲ trial, that compared gemcitabine 
vs observation in adjuvant treatment, had similar 
results: no correlation between hENT1 expression and 
disease free survival (DFS) or OS was observed[30]. The 
reasons for these conflicting results are still unclear, 
and might either be due to the use of different types 
of hENT1 antibodies between studies, or to nonlinear 
protein expression pattern changes related to the 
disease-stage, since tumor genetic landscapes are 
highly dynamic during cancer progression. A validated 
immunohistochemical protocol and appropriate samp-
ling, using metastatic cohorts, are required to further 
evaluate the role of hENT1 in predicting response to 
gemcitabine.
All the other studies evaluating various potential 
biomarkers for gemcitabine activity are retrospective, 
monocentric, without multiple correction or validation 
in broader populations. Moreover, most studies used 
different methods and specimens, without appropriate 
validation as well as evaluation of tumor heterogeneity 
and possible evolution of cancer cells after relapse[31]. 
In conclusion, after almost twenty years of use in the 
clinical practice, currently no prognostic biomarkers are 
available to stratify survival outcomes for pancreatic 
cancer patients receiving gemcitabine.
FOLFIRINOX treatment
FOLFIRINOX is a combination of the chemotherapy 
agents 5-FU, leucovorin, irinotecan and oxaliplatin. 
This schedule was introduced as a novel standard in 
first-line treatment of metastatic pancreatic cancer 
after the publication of the PRODIGE 4/ACCORD 11 
trial, which compared FOLFIRINOX with gemcitabine. 
The combination was first investigated in a phase I 
trial assessing the feasibility of FOLFIRINOX: most of 
the objective responses were found in gastrointestinal 
malignancies, in particular in two cases of pancreatic 
cancer[32]. In a phase Ⅱ trial 46 patients receiving 
FOLFIRINOX for advanced pancreatic cancer showed 
a response rate of 26%, including 4% complete 
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univariate analysis ECOG PS 1, male gender, body or 
tail primary tumor, hepatic metastases, synchronous 
metastases, and low baseline albumin were identified 
as independent negative prognostic factors[34]. However, 
in the multivariate analysis synchronous metastases, 
hepatic metastases, low baseline albumin level (< 
3.5 g/dL) and age > 65 years were identified as 
independent negative prognostic factors for overall 
survival, using the Cox regression model stratified 
on ECOG performance status and location of primary 
tumor and adjusted on pulmonary metastases, as 
summarized in the Table 1.
Similar to the previous gemcitabine-based regimens, 
clinicians are lacking predictive biological markers to 
help choosing which individual patient will benefit from 
FOLFIRINOX or FOLFIRINOX-modified treatments. 
Potential candidates include determinants of drug 
metabolism and activity (Figure 1B), such as the 
enzyme of 5-FU catabolism dihydropyrimidine dehydro-
genase (DPD), and the target enzyme thymidylate 
synthase (TS)[42]. For instance, Kurata et al[43] analyzed 
15 pancreatic cancer cell lines and two 5-FU-resistant 
sub-lines to demonstrate a significant association 
between 5-FU sensitivity and the mRNA expression of 
both TS and DPD. These data suggests that pancreatic 
cancer cells with high TS and/or DPD levels are more 
resistant to 5-FU. An immunohistochemical analysis 
of 68 resected pancreatic cancer tissues showed 
that patients with low DPD protein levels reached a 
significantly higher survival rate when treated with 
adjuvant 5-FU liver perfusion chemotherapy[44]. 
However, no data on the prognostic value of DPD are 
currently available for the metastatic disease. Another 
immunohistochemical study evaluated TS expression 
both in primary and metastatic lesions. Surprisingly, 
in resectable patients, high TS expression levels were 
significantly correlated with a longer OS rate, vs lower 
OS for negative or low TS expression levels. Conversely, 
high TS immunoreactivity did not significantly influence 
the OS of the patients with unresectable tumors, nor 
was an independent prognostic factor[45]. 
Data on potential biomarkers for the efficacy of 
platinum compounds in metastatic pancreatic cancer 
are still unclear (Figure 1B). It has been demonstrated 
that cells able to repair platinum-DNA adducts present 
a profile of resistance to these drugs. The nucleotide 
excision repair (NER) system, which consists of at 
least 30 identified polypeptides, including ERCC1 
and XPD, play a key role in removal of damaged 
DNA[46]. A recent study in patients receiving upfront 
off-protocol gemcitabine/oxaliplatin plus erlotinib, 
showed that high ERCC1 expression correlated with 
response rate. However, due to the small number of 
patients (n = 51) evaluable for immunohistochemical 
staining, the correlation with OS did not reach the 
level of statistical significance[47]. Furthermore, the 
clinical role of ERCC1 staining as a biomarker for resis-
tance to platinum drugs is limited by methodological 
issues since immunohistochemical analysis with the 
currently available ERCC1 antibodies is not specific 
to detect the unique functional ERCC1 isoform[48]. 
Previous studies in more than 240 metastatic patients 
treated with cisplatin/capecitabine/gemcitabine-
based polychemotherapeutic regimens showed that 
patients harboring the XPD Gln751Gln genotype had a 
worse prognosis[49,50]. A subgroup of patients treated 
with gemcitabine monotherapy lacked a correlation 
between XPD-Lys751Gln polymorphism and outcome, 
suggesting that the NER system does not affect the 
repair of gemcitabine-induced DNA damage. No data 
are available on subgroups of patients treated only 
with platinum compounds. Therefore, the role of this 
specific polymorphism in the activity of regimens 
with platinum compounds combined with different 
anticancer agents is yet unclear. 
Finally, a few studies evaluated some potential 
biomarkers of irinotecan in pancreatic cancer cells and 
tissues (Figure 1B). Resistant pancreatic tumor cells 
have shown decreased mRNA levels of the irinotecan 
target topoisomerase-I (TOP1) compared to their 
parental cell lines[51]. However, neither expression 
of TOP1, nor expression of the molecules that are 
involved in its export (ABCB1, ABCC2) or inactivation 
(CYP3A4, CYP3A5, UGT1A10), yielded a statistically 
significant correlation with irinotecan sensitivity in a 
panel of pancreatic cancer cell lines[52]. A recent study 
showed that 30% of pancreatic cancer tissues have 
increased TOP1 copy numbers suggesting further 
analyses on the association between TOP1 gene copy 
number and irinotecan efficacy in the clinical setting[53]. 
A more comprehensive study including in vitro, in 
vivo models as well as extensive analyses of genetic 
databases, proteomics and tissue microarrays (TMAs) 
focused on carboxyl esterase-2 (CES2), which activates 
irinotecan into SN-38. This study showed that high 
expression of CES2 was associated with longer OS and 
PFS in resectable and borderline resectable patients 
treated with FOLFIRINOX in the neoadjuvant setting[52]. 
Remarkably, this is the first study reporting the as-
sociating of molecular features of pancreatic tumors 
and outcome of FOLFIRINOX treatment. However, the 
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Table 1  Main prognostic factors reported in the MPACT and 
in PRODIGE 4/ACCORD 11 trials at multivariate analysis
Prognostic factors for metastatic pancreatic patients treated with 
Gemcitabine-nab-paclitaxel FOLFIRINOX
Age < 65 yr Age > 65 yr 
(HR = 0.81; P = 0.019) (HR = 1.47; P < 0.019)
Hepatic metastases Hepatic metastases
(HR = 1.81; P < 0.001) (HR = 1.58; P = 0.051)
Number of metastatic sites > 3 Synchronous metastases
(HR = 1.08; P = 0.86) (HR = 2.47; P < 0.003)
KPS score, 70-80 vs 90-100 Low baseline albumin level
(HR = 1.60; P < 0.001) (HR = 1.85; P < 0.001)
Region - Eastern Europe 
(HR = 1.22; P = 0.077)
KPS: Karnofsky performance status.
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univariate and multivariate analyses were limited by 
the small number of patients (n = 22). Moreover, the 
expression data of resectable patients might not be 
comparable to the data from a population of patients 
suffering from metastatic disease. Therefore, other 
potential biomarkers of FOLFIRINOX therapy remain to 
be explored, especially in the metastatic setting.
Nab-paclitaxel and gemcitabine combination
In September 2013, the United States Food and Drug 
Administration approved the cytotoxic agent nab-
paclitaxel for first-line treatment of patients with 
metastatic adenocarcinoma of the pancreas in com-
bination with gemcitabine.
Nab-paclitaxel is a nanoparticle albumin-bound 
paclitaxel, which seems to achieve an higher tumor 
accumulation vs paclitaxel, by both of the lack of 
drug-sequestering solvent micelles and the albumin-
mediated transcytosis[54]. The presence of albumin-
binding proteins, such as secreted protein acidic and 
rich in cysteine (SPARC), which is overexpressed in the 
stromal fibroblasts surrounding the tumor tissue, is 
another hypothesized mechanism to be responsible of 
the higher tumor accumulation of this drug[55]. 
A few potential molecular mechanisms underlying 
the synergistic effect of the combination of nab-
paclitaxel and gemcitabine have also been identified. 
Evidence suggests that Nab-paclitaxel targets tumor 
stroma, which represents a substantial barrier to 
the perfusion and diffusion of gemcitabine[56,57]. The 
synergistic effect also seems to be related to the 
inactivation by nab-paclitaxel of cytidine deaminase: a 
gemcitabine catabolizing enzyme, which increases, as 
a consequence, intratumoral gemcitabine levels[58]. 
The efficacy and safety data of the combination 
of nab-paclitaxel and gemcitabine were tested in a 
phase Ⅰ-Ⅱ study, enrolling a total of 67 patients. The 
median PFS for all patients was 7.1 mo with a median 
OS of 10.3 mo. Hematologic grade 3 toxicities were 
quite common, comprising 67% of neutropenia and 
23% of thrombocytopenia Interestingly, the response 
rate was 46%. Furthermore, in the 36 patients 
evaluable for SPARC, high SPARC expression correlated 
with significantly longer OS[59].
After this promising phase Ⅰ-Ⅱ trial, the phase Ⅲ 
trial enrolled 861 patients, which were randomized 
to receive the combination of nab-paclitaxel and 
gemcitabine or gemcitabine monotherapy. The median 
OS was 8.5 mo vs 6.7 mo, respectively, favouring 
the combination of nab-paclitaxel and gemcitabine 
(P < 0.001). The PFS was significantly longer for the 
combination of nab-paclitaxel and gemcitabine (5.5 mo 
vs 3.7 mo, P < 0.001)[60]. A list of prognostic factors is 
reported in the Table 1.
To investigate a potential predictive/prognostic 
role of SPARC expression, tissue was collected in 
this study. Using an immunohistochemical assay, 
86% concordance was reported compared to the 
assay employed in the phase Ⅰ/Ⅱ trial. SPARC was 
measured in the tumor stroma (256 patients), tumor 
epithelia (301 patients) and plasma (343 patients). 
Stromal SPARC was deemed as high in 71 patients 
and low in 185 patients and was not associated with 
OS, both in the univariate and in the multivariate 
analysis. Similarly, epithelia and plasma SPARC were 
not associated with outcome. Therefore, SPARC failed 
as a predictive biomarker and as a potential selection 
criteria for treatment with nab-paclitaxel[61].
Two recent studies revealed that depletion of stromal 
cells can lead to a more biologically aggressive form 
of PDAC with poorly differentiated histology, increased 
vascularity and proliferation. In contrary depletion 
of carcinoma-associated fibroblasts (CAFs) induces 
immunosuppression and is associated to epithelial to 
mesenchymal transition[62]. These data suggest that 
stromal factors can differentially influence PDAC growth 
and further studies on the potential prognostic and/or 
predictive role of components of both the tumor and its 
microenvironment are warranted.
Other potential biomarkers have been explored 
among key determinants of paclitaxel activity (Figure 
1A). In particular, the role of tubulin in resistence to 
taxane therapy has been widely investigated. Class Ⅲ 
beta-tubulin (TUBB3) seems to be involved in taxane-
based chemo-resistance and linked to taxane resistance 
in NSCLC. In addition, in stage Ⅲ and Ⅳ NSCLC, 
receiving taxanes or other chemotherapy agents, beta-
tubulin has been assessed by immunohistochemistry 
on tumor samples. Low tumor levels of class Ⅲ B-tubulin 
isotype had a better response rate, longer PFS and 
OS, and this variable was not found to be predictive 
in patients receiving regimens without taxanes[63]. 
The role of tubulin expression was also investigated in 
gastric cancer: 146 gastric cancer patients receiving 
taxane-based chemotherapy showed a significantly 
shorter median PFS if TUBB3 expression was high, 
compared to low TUBB3 expression; in multivariate 
analysis TUBB3 expression was related to a shorter 
PFS[64].
Cytochrome P450 CYP2C8 is the main enzyme in 
the metabolic inactivation of paclitaxel. In vitro studies 
showed induction of this enzyme in cells with acquired 
resistance to paclitaxel[65] and that recombinant 
CYP2C8*3 is less efficient in paclitaxel metabolism 
than the CYP2C8*1 allele. However, this polymorphism 
was not statistically significantly correlated to OS in 
119 patients treated for ovarian cancer with paclitaxel/
carboplatin[66]. 
NOVEL TREATMENTS 
Pancreatic cancer is a tumor characterized by a 
dense stromal component. The stroma comprises 
many components, both cellular and acellular: 
pancreatic stellate cells, immune cells, fibroblast, 
myofibroblast, blood vessels and extracellular matrix. 
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All these heterogeneous components within the tumor 
microenvironment, seem to be involved in cancer 
proliferation, metastasis and resistance to therapy[67]. 
For instance, the formation of the extracellular 
matrix, made up of proteoglycans, hyaluronic acid 
and collagen, has several consequences on blood 
vessels distribution inside the tumoral lesion[68]. The 
excessive accumulation of hyaluronic acid increases 
the interstitial fluid pressure compressing the blood 
vessels, consequently causing reduced drug delivery 
and chemoresistance[57]. Against this background, 
drugs targeting the stromal compartment are therefore 
under extensive investigation, as well as drugs 
targeting several key pathways emerging from the 
deep molecular profiling provided by the most recent 
genetic analyses. A list of the phase Ⅲ trials with new 
experimental compounds performed in pancreatic 
cancer is presented in the Table 2.
Targeting the vascular endothelial growth factor pathway 
Although vascular pattern seems to be basically altered 
in pancreatic cancer and this type of tumor seems to 
be able to survive despite a relatively low blood flow, 
the vascular endothelial growth factor (VEGF) pathway 
has been targeted in several studies.
The anti-VEGF antibody bevacizumab was used 
in pancreatic cancer in combination with gemcitabine 
in two phase Ⅲ studies. In a first study bevacizumab 
was combined with gemcitabine in a phase Ⅲ placebo 
controlled study, without obtaining any advantage both 
in PFS and OS[69]. Given the improved OS registered 
with the combination of gemcitabine and erlotinib, 
bevacizumab was also tested in combination with 
this doublet: 301 patients received the gemcitabine, 
erlotinib and placebo combination and 306 patients 
received the combination containing bevacizumab. 
A statistically significant increase in PFS emerged, 
but improvement of the primary endpoint (OS) was 
not met[70]. Despite these failures, a phase Ⅲ study 
tested the combination of gemcitabine with afliber-
cept, which is a recombinant fusion protein consisting 
of VEGF-binding portions from the extracellular 
domains of human VEGF receptors (VEGFR) 1 and 
2. Unfortunately this trial was ended prematurely for 
futility after an interim analysis of OS[71].
Other clinical trials evaluated small molecules, such 
as axitinib. Axitinib is an oral inhibitor of VEGFR-1, 
2 and 3. This was tested in a randomized phase Ⅱ 
trial in combination with gemcitabine vs gemcitabine 
monotherapy. A longer but not statistically significant 
OS was detected with the combination therapy of 
gemcitabine and axitinib (6.9 mo vs 5.6 mo)[72]. 
Subsequently, a phase Ⅲ trial was started comparing 
gemcitabine plus axitinib or placebo. No difference 
was observed in the OS of the patients treated within 
these two arms (8.5 mo vs 8.3 mo) and concluded 
that axitinib was deemed not effective in pancreatic 
cancer[73]. 
The multi-target kinase inhibitor sorafenib acts by 
inhibiting both VEGFR-2 and VEGFR-3, and PDGFR and 
RAF kinase. This results in an antiangiogenic action as 
well as in the disruption of the KRAS-BRAF-MEK-ERK 
pathway. Given the high prevalence of KRAS mutations 
in pancreatic cancer the use of this compound has a 
strong rationale. Despite these premises no advantage 
in PFS or OS emerged when combining sorafenib 
with gemcitabine in the phase Ⅲ BAYPAN study[74]. 
These disappointing results could be explained by 
upregulation of pathways that may circumvent BRAF 
inhibition, particularly in KRAS-mutated tumors, as 
demonstrated in preclinical melanoma models[75].
Notably, all these trials demonstrated negative 
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Table 2  Phase Ⅲ clinical trials with new targeted anticancer agents combined with gemcitabine-based chemotherapy in metastatic 
pancreatic cancer patients
Ref. Treatment arms Patients Results
Kindler et al[69] J Clin Oncol 2010 Gemcitabine + bevacizumab vs gemcitabine + placebo 302 OS: 5.8 mo vs 5.9 mo (P = 0.95)
PFS: 3.8 mo vs 2.9 mo (P = 0.07)
300 RR: 13% vs 10% (P = NR)
Van Cutsem et al[70] J Clin Oncol 2009 Erlotinib + gemcitabine + bevacizumab vs 
erlotinib + gemcitabine + placebo
306 OS: 7.1 mo vs 6.0 mo (P = 0.2087)
PFS: 4.6 mo vs 3.6 mo (P = 0.0002)
301 RR: 13.5% vs 8.6% (P = 0.0574)
Rougier et al[71] Eur J Cancer 2013 Gemcitabine + aflibercept vs gemcitabine + placebo 271 OS: 6.5 mo vs 7.8 mo (P = 0.2034)
PFS: 3.7 mo vs 3.7 mo (P = 0.8645)
275 RR: NR
Kindler et al[73] Lancet Oncol 2011 Gemcitabine + axitinib vs gemcitabine + placebo 316 OS: 8.5 mo vs 8.3 mo (P = 0.5436)
PFS: 4.4 mo vs 4.4 mo (P = 0.5203)
316 RR: 5% vs 2% (P = 0.0180)
Gonçalves et al[74] Ann Oncol 2012 Gemcitabine + sorafenib vs gemcitabine + placebo   52 OS: 8.0 mo vs 9.2 mo (P = 0.231)
PFS: 3.8 mo vs 5.7 mo (P = 0.902)
  52 RR: 23% vs 19% (P = NR)
Philip et al[94] J Clin Oncol 2010 Gemcitabine + cetuximab vs gemcitabine 372 OS: 6.3 mo vs 5.9 mo (P = 0.19)
PFS: 3.4 mo vs 3.0 mo (P = 0.18)
371 RR: 14% vs 12% (P = 0.59)
OS: Overall survival; PFS: Progression free survival; RR: Response rate; NR: Not reported.
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results in using anti-VEGF pathway compounds, sugge-
sting that pancreatic cancer is independent from conven-
tional angiogenesis. However, all these studies used an 
unselected population, without identifying a predictive 
biomarker of response, also because no validated 
biomarkers of antiangiogenic therapies are available 
for routine clinical use. Research on biomarkers that 
can guide for successful anti-angiogenesis treatments 
represents an important challenge not only for pancreatic 
cancer.
Targeting tumor stroma 
With the emergence of the pancreatic cancer microenvi-
ronment as an essential ingredient of this malignancy, 
therapies targeting its dense stromal reaction have 
begun to be designed and applied in the clinic. 
Remarkably, nab-paclitaxel was designed as a 
cytotoxic agent directed to SPARC, and so targeting a 
stroma component. Data about the stromal disruption 
after nab-paclitaxel are promising: in 16 patients with 
resectable pancreatic cancer who underwent two cycles 
of nab-paclitaxel and gemcitabine the tumor response 
was evaluated by PET scan and CA19.9 levels, 
while the effect on tumor stroma was evaluated by 
Endoscopic Ultrasound Elastography (EUS) and on the 
histology specimen after resection. The results were 
compared with untreated patients or patients treated 
with conventional therapy. A significant decrease in 
tumor stiffness was detected by EUS, and the analysis 
of the tumor stroma in resected specimens showed 
disorganized collagen and low density of CAFs[76].
An interesting target among stroma components is 
hyaluronic acid, which can be targeted by PEGylated 
Recombinant Human Hyaluronidase (PEGPH20). This 
agent has been tested in combination with gemcitabine 
in a phase Ib study enrolling 28 patients: the PFS and 
OS for the entire population were respectively 5.0 and 
6.6 mo. In a subgroup of patients (n = 17), the tissue 
hyaluronan (HA) levels at baseline were evaluated. 
Interestingly, PFS and OS were 7.2 and 13.0 mo for 
"high"-HA expressing patients[77]. A randomized phase 
ⅠB/Ⅱ study evaluating the addition of PEGPH20 to 
modified FOLFIRINOX vs modified FOLFIRINOX alone 
is currently recruiting patients[78]. The interim results 
of another randomized phase Ⅱ study in metastatic 
pancreatic cancer patients treated with the combination 
of gemcitabine and nab-paclitaxel with PEGPH20 or the 
standard doublet alone, already showed that patients 
with high HA levels had significantly better ORR and 
PFS when treated with the triplet-drug combination 
than with nab-paclitaxel and gemcitabine alone. This 
evidence supports future studies to investigate HA as a 
predictive factor of response[79]. 
Despite these promising results, stromal depletion 
strategies should be used with caution[80]. Deletion 
of Sonic Hedgehog (Shh) can decrease the stromal 
component in PDAC, but might also contribute to a 
more aggressive tumor behavior. By deleting Shh 
in a mouse model, the reduced stromal component 
was indeed coupled to increased aggressiveness 
and vascularity of the tumor. Additionally, a VEGFR 
inhibitor selectively improved survival in Shh-deficient 
tumors, suggesting that some component of the 
stroma can limit the tumor growth by suppressing 
angiogenesis[81]. These data might explain the negative 
results obtained with the Shh inhibitor, IPI926, which 
has been investigated in phase Ⅰ and phase Ⅱ trials. 
The first study, that tested IPI926 in combination with 
FOLFIRINOX was prematurely ended, despite a good 
response rate of 67%, due to a separate phase Ⅱ study 
in combination with gemcitabine that demonstrated a 
detrimental effect of the combination[82]. 
Another potential target is the connective tissue 
growth factor (CTGF), that is usually overexpressed 
in the stroma surrounding pancreatic cancer[80]. The 
use of the monoclonal antibody FG-3019 targeting 
the CTGF increased the response to gemcitabine in 
murine models of pancreatic cancer[83]. In the clinical 
setting, FG-3019 has been combined to gemcitabine 
and erlotinib in 75 locally advanced and metastatic 
pancreatic cancer patients. The combination was well 
tolerated and the OS for the whole study population 
was 9.4 mo, with 3% of complete response and 52% 
of partial response rate[84]. Therefore, a phase Ⅰ
/Ⅱ trial of gemcitabine plus nab-paclitaxel with or 
without FG-3019 as neoadjuvant chemotherapy in 
locally advanced, unresectable pancreatic cancer 
is currently ongoing[85]. Remarkably, the baseline 
plasma CTGF correlated inversely with OS, warranting 
further investigation. A randomized phase Ⅱ trial 
of FG-3019 combined with gemcitabine plus nab-
paclitaxel vs chemotherapy alone in patients with 
marginally inoperable pancreatic cancer is currently 
recruiting patients[86]. Finally, a phase Ⅰ trial on 
the χ -secretase inhibitor MK-0752, that blocks the 
NOTCH pathway, administered in combination with 
gemcitabine, in patients with with Stage Ⅳ pancreatic 
ductal adenocarcinoma showed the feasibility of this 
combination and the initial data on clinical activity 
prompted further investigations, especially in patients 
who initially respond to and tolerate gemcitabine well, 
but develop resistant disease[87].
Targeting HER-2 and EGFR 
Co-expression of EGFR and HER-2 receptor has 
been related to invasion and worse clinical outcome 
in pancreatic cancer[88]. Furthermore, strong HER-3 
expression seems to be related to short survival[89]. 
A report that investigated the co-expression of 
HER-2 (by immunohistochemistry and FISH) in EGFR 
positive pancreatic cancer, suggested that HER-2 is an 
important cooperating member of the EGFR pathway 
since overexpression of HER-2 was detected in 17% of 
the whole population and 24% of EGFR-overexpressing 
tumors. Conversely none of EGFR negative tumors had 
a overexpressed or amplified HER-2[88]. The subsequent 
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trial on the combination of the monoclonal anti-HER-2/
neu receptor trastuzumab with gemcitabine showed 
HER-2 overexpression in about 16% of the samples. In 
agreement with previous favourable results in breast 
cancer[90], the patients were selected according to 
the immunohistochemistry expression of HER-2 (2+ 
and 3+). However, partial response was reported in 
only 6% of patients, and the median OS was 7 mo[91]. 
Trastuzumab was also tested in combination with 
capecitabine in a phase Ⅱ trial. This study reported 
HER-2+ and 3+ overexpression or gene amplification 
in 11% of patients, but only 64% of patients with 
HER-2 and 3+ expression showed gene amplification. 
The effect on the PFS and OS were not satisfactory, 
so further evaluation of this targeted therapy was not 
suggested by the authors[92]. In addition, a phase Ⅱ 
study evaluating the combination of the dual HER2/neu 
and EGFR tyrosine kinase lapatinib and gemcitabine in 
an unselected population, was closed due to a futility 
analysis[93]. 
Disappointing results were also observed in a large 
phase Ⅲ trial comprising patients with metastatic or 
locally advanced pancreatic cancer who were randomly 
assigned to receive gemcitabine and cetuximab or 
gemcitabine monotherapy. No difference was detected 
for OS, response rate or PFS between the two groups. 
The population was not selected according to a 
biomarker, but EGFR expression was evaluated on 
595 patients and detected in 90%: the EGFR positive 
patients showed no clinical benefit either[94].
Despite this failure, a two-stage study of PEGPH20 
and cetuximab in patients with pancreatic adeno-
carcinoma prior to surgical resection is currently 
ongoing[95]. Moreover, a randomized phase Ⅱ trial is 
currently recruiting patients undergoing treatment 
with gemcitabine monotherapy and gemcitabine plus 
afatinib, which is an oral EGFR1 and HER-2/HER-4 
inhibitor. Of note, a translational project is included in 
the study in order to select patients who can benefit 
from the combination treatment[96].
Targeting MEK and mTOR
The most known driver mutation in the progression of 
pancreatic cancer is mutated KRAS, which is present in 
up 85% of the patients. New molecules and therapeu-
tic strategies to effectively inhibit KRAS are under 
investigation, but up to now no agent has successfully 
targeted KRAS or KRAS downstream pathways, such 
as mitogen-activated protein kinase kinase (MEK or 
MAPK/ERK kinase) or mTOR.
For instance, the MEK1/2 inhibitor CI-1040 has been 
evaluated in a phase Ⅱ study including 15 pancreatic 
cancer patients. This drug demonstrated insufficient 
antitumor activity to warrant further evaluation[97]. 
Selumetinib has been evaluated in a phase Ⅱ study 
comparing this MEK inhibitor in monotherapy vs cape-
citabine in the second-line setting, after a gemcitabine-
based regimen. This trial showed a good safety 
profile, but no difference in OS emerged between 
the two arms[98]. MEK inhibitors have also been also 
investigated in combination with chemotherapy: the 
combination of trametinib and gemcitabine vs placebo 
and gemcitabine in the first-line setting. This trial did 
not show any significant difference in outcome and no 
difference was observed also in KRAS mutation-positive 
patients[99]. Similarly, the combination of pimasertib 
and gemcitabine did not result in any advantage in 
the clinical outcome vs gemcitabine and placebo[100]. 
A recent preclinical study showed that pimasertib 
reduced ribonucleotide reductase subunit 1 protein, 
which is a target of gemcitabine[101]. However, this 
protein was not evaluated in patients’ specimens, while 
KRAS mutational status did not influence the results. 
Conversely, in a randomized phase Ⅱ trial evaluating 
refametinib and gemcitabine combination vs placebo, a 
trend toward a significantly longer OS, PFS and better 
ORR was observed in the subgroup of patients with 
KRAS wild type profile[102].
Feedback mechanisms triggered by MEK inhibitors 
can activate the EGFR and PI3K oncogenic pathways. 
This prompted the investigation of specific combination 
strategies[103], but the combination of EGFR and MEK 
inhibitors showed modest antitumor activity in previously 
treated pancreatic cancer patients. In particular, a phase 
Ⅱ study combining erlotinib and selumetinib showed no 
objective response, a PFS of 1.9 mo and an OS of 7.3 
mo. Interestingly, patients with an epithelial phenotype 
(i.e., with high level of E-cadherin expression) seemed 
to be more sensitive to the treatment, suggesting that 
further translational studies could identify subgroups of 
patients more likely to benefit from this treatment[104]. 
However, these combinatorial approaches can be limited 
by increased toxicity. Indeed, a phase I study of trame-
tinib combined with mTOR inhibitor everolimus showed 
promising partial response and stable disease rates, of 7 
and in 31% of cases, respectively, in the 21 pancreatic 
cancer patients enrolled in the trial. Unfortunately, the 
occurrence of severe treatment-related adverse events 
did not allow identifying a dose for a following phase Ⅱ 
trial[105].
Targeting the c-MET pathway
The overexpression of the tyrosine kinase receptor c-Met 
and its ligand, HGF, have been associated with cellular 
proliferation and survival in different tumor types[106]. In 
pancreatic cancer c-Met expression has been correlated 
to TNM stage, poor tumor differentiation, increased 
abnormal angiogenesis and shorter OS [107].
This receptor has been identified as a marker of 
pancreatic cancer stem cells (CSCs), which play a 
pivotal role in metastatic behaviour, and intrinsic chemo-
resistance[108]. Moreover, c-Met has been associated 
to the mesenchymal support network and EMT-like 
changes that characterize the cells with acquired 
resistance to gemcitabine[109]. The HGF-c-Met pathway 
has also been identified as a possible mediator of the 
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neoangiogenic effects of cancer-associated human 
pancreatic stellate cells[110]. Furthermore HGF increases 
the production of VEGF by stromal cells and interacts 
with VEGF to support endothelial cells proliferation[111]. 
Recent preclinical studies showed the ability of the 
c-Met inhibitor crizotinib to specifically target CSC-
like subpopulations and synergistically interact with 
gemcitabine, while cabozantinib slowed tumor growth 
and reduced the population of CSCs increasing the 
efficacy of gemcitabine even in high-resistant cells[112,113]. 
However, a more recent study on the inhibition of 
HGF using the neutralizing antibody AMG102 showed 
that this therapeutic strategy was more effective than 
gemcitabine in inhibiting tumor metastasis, but this 
effect was lost when combined with chemotherapy. 
These data suggest that gemcitabine selects a subpo-
pulation of cells with CSCs and EMT features[114]. 
Several clinical trials on the combination of cabozan-
tinib and gemcitabine are currently ongoing in advanced 
cancers, including pancreatic cancer (NCT01744652, 
NCT01548144, NCT01531361, NCT01999972, 
NCT01663272) and the results of a recently completed 
randomized phase II trial of tivantinib vs gemcitabine 
in patients with advanced pancreatic cancer are 
awaited[115].
Targeting the JAK-STAT pathway
A recent study showed that targeting the Janus-
activated kinase-2 (JAK2) signalling pathway in 
pancreatic cancer inhibits the proliferation of pancreatic 
cancer cells. JAK2 can indeed activate the transcriptional 
factor signal transducer and activator of transcription 
3 (STAT3), which is leading one of the signalling 
mechanisms involved in pancreatic carcinogenesis; as 
well as to angiogenesis, cell proliferation and metastasis 
in various malignancies[116]. Furthermore, JAK-STAT 
pathway is a mediator of multiple inflammatory 
responses both in the tumor and in the host tissues, 
involved in the cachexia response[117]. 
The potent JAK-1 and JAK-2 inhibitor ruxolitinib was 
tested in a randomized phase Ⅱ study in patients who 
underwent failure to a gemcitabine-containing first-line 
treatment, who were randomized to receive ruxolitinib 
in combination with capecitabine vs capecitabine and 
placebo. In the whole population of 127 patients no 
difference in OS or PFS was detected between the two 
arms, but in a pre-specified subgroup analysis it was 
shown that patients with higher levels of C-reactive 
protein (> 13 mg/L) had an HR for OS of 0.47 while 
the HR for OS in patients with levels lower or equal 
to 13 mg/L was 0.89. Remarkably, additional post-
hoc analyses which categorized patients according 
to mGPS (Glasgow Prognostic Score) status (based 
on C-reactive protein and albumin levels), showed a 
meaningful separation in OS between the ruxolitinib 
and capecitabine groups with increasing mGPS[118]. 
Based on these results, two phase Ⅲ studies are 
ongoing to investigate the activity of ruxolitinib and 
capecitabine after failure of a first-line treatment, in 
patients with metastatic pancreatic cancer and an 
mGPS status of 1 or 2[119,120].
ROLE OF MIRNAS AS NOVEL POTENTIAL 
BIOMARKERS
Since pancreatic cancer is such a dismal disease, any 
biomarker that can help to better stratify patients 
might have crucial clinical applications. Moreover, 
considering that the therapeutic options that have 
been made recently available for metastatic pancreatic 
cancer patients provide almost identical disease control 
and similar survival, novel biomarkers are required to 
aid treatment decisions.
High impact bench-to-bedside research on hundreds 
of patient samples improved prognostic capabilities in 
several tumor types, such as breast cancer[121]. Similar 
studies are more difficult to perform in pancreatic 
cancer, which is less common disease, characterized 
by dense stromal reaction and very small amounts of 
tumor tissue available. 
The discovery of miRNAs has unraveled new 
mechanisms for regulation of gene expression and 
has provided new directions for the quest of cancer 
biomarkers[122]. MiRNAs are potentially ideal biomarkers, 
as they are stable molecules, tumor and tissue specific, 
and can be detected with different techniques in a very 
small amount of tissue.
The pivotal regulatory role of each miRNA in 
controlling expression of multiple gene transcripts 
offers a unique opportunity of identifying critical 
miRNAs as informative biomarkers for detection, 
diagnosis and prognosis of tumors that result from 
deregulation of multiple genes. Expression profiling 
data have created diagnostic and prognostic signatures 
for a variety of tumor types[123]. Furthermore, selected 
miRNAs may influence response to chemotherapy[124].
Although the PDAC miRNome has been extensively 
profiled[125], it remains unclear which differentially 
expressed miRNAs are most important in the clinical 
outcome. In particular, only a few studies evaluated 
the role of candidate miRNAs to predict the sensitivity/
resistance to the drugs of the FOLFIRINOX and gem-
citabine/nab-paclitaxel regimens.
The epithelial and stromal expression of miR-21 
was assessed by in situ hybridization (ISH) in 229 
patients from a phase Ⅲ randomized trial comparing 
5-FU to gemcitabine before and after 5-FU-based 
chemoradiation therapy (RTOG 9704). Remarkably, 
higher levels of miR-21 expression in CAFs correlated 
with shorter OS in the patients treated with 5-FU, 
but not gemcitabine[126]. These data are in contrast 
with a previous study assessing miR-21 expression 
by PCR in two independent cohorts of patients, 
treated with various gemcitabine or 5-FU containing 
adjuvant regimens, suggesting that miR-21 expression 
can affect outcome of both gemcitabine and 5-FU-
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based treatment[127]. Similarly, PCR data on laser-
microdissected specimens demonstrated a correlation 
between a high expression of miR-21 with worse 
outcome after gemcitabine treatment in both radically-
resected and metastatic patients, as well as in a 
cohort of pancreatic cancer arising from intraductal 
papillary mucinous neoplasms of the pancreas[128,129]. 
These results might be explained by several effects 
of miR-21 overexpression on preclinical models of 
pancreatic cancer, including inhibition of apoptosis 
and induction of cell proliferation and invasion, as 
well as chemoresistance to both gemcitabine and 
5-FU[128,130]. More recently, other two miRNAs (miR-23a, 
and miR-27a) were added to miR-21 to identify a 
combination of miRNA that acted as cooperative 
repressors of a network of tumor suppressor genes[131]. 
In 91 PDAC samples from gemcitabine-treated 
radically resected patients, high levels of this triple 
miRNA combination were associated with shorter OS. 
Thus, the role of miR-21 as prognostic or predictive 
biomarker for 5-FU and/or gemcitabine is still under 
debate and data from a study on larger cohorts 
of patients, using validated methods, are urgently 
awaited. 
Other potential biomarkers related to miRNA 
effects in patients treated with 5-FU as well as to the 
other drugs of the FOLFIRINOX regimens have been 
investigated in metastatic patients affected by different 
tumor types, but not in pancreas. In particular, a 
pharmacogenetic study on 18 polymorphisms in miRNA-
containing genomic regions (primary and precursor 
miRNA) and in genes related to miRNA biogenesis in 61 
patients with metastatic colorectal cancer treated with 
5-FU and irinotecan. The polymorphism rs7372209 in 
pri-miR26a-1 was associated with a higher response 
and longer OS, while the polymorphism rs1834306, 
located in the pri-miR-100 gene, correlated with a 
longer PFS[132]. A more extensive study profiled 742 
miRNAs in laser-capture microdissected samples 
from 26 patients receiving 5-FU or capecitabine 
combined with oxaliplatin for metastatic colorectal 
cancer. This study suggested that overexpression of 
miR-625-3p, miR-181b and miR-27b was associated 
with lower response rate. In a validation cohort of 
94 patients treated with capecitabine and oxaliplatin, 
high expression of miR-625-3p was confirmed to 
be associated with poor response rate[133]. However, 
different results emerged from a study evaluating 754 
miRNAs in a screening (n =  212) and validation (n 
=  121) cohort of metastatic colorectal cancer patients 
treated with the first line combination of capecitabine, 
oxaliplatin and the VEGF inhibitor bevacizumab[134]. 
Higher miR-664-3p expression and lower miR-455-5p 
expression were predictive of longer OS, while higher 
expression of miR-196b-5p and miR-592 predicted 
improved OS regardless of bevacizumab treatment in a 
control cohort of 127 patients.
No data are yet available on miRNA affecting nab-
paclitaxel, but several miRNAs have been associated 
to resistance to paclitaxel, which is currently used for 
treatment of various cancers. A study in 82 patients 
with metastatic or recurrent gastric cancer receiving 
first-line chemotherapy with fluoropyrimidine combined 
with paclitaxel or oxaliplatin showed that patients 
with miRNA27a overexpression had a significantly 
shorter OS[135]. More recently, the Nanostring miRNA 
array was used to evaluate tumor tissues from 115 
of 823 patients enrolled in the Intergroup trial E2603, 
which randomized metastatic melanoma patients to 
carboplatin and paclitaxel with or without sorafenib[136]. 
High levels of miR-659-3p expression were correlated 
to responsive compared to stable disease, supporting 
future studies on this potential predictive biomarker in 
different tumor types.
Several preclinical studies suggest the role of many 
other miRNAs in the activity of the chemotherapeutics 
drugs used for the first-line treatment of metastatic 
pancreatic cancer, as illustrated in the Table 3. 
However, as with previous studies on gene profiling, 
most miRNAs correlated to chemoresistance are not 
overlapping and no conclusive evidence has yet been 
obtained about their clinical use. These controversial 
data might be explai00pned by the different samples 
(frozen vs paraffin-embedded, micro- vs non-micro-
dissected), experimental platforms (quantitative 
PCR vs miRNA array or ISH), stage, and regimens, 
as well as small cohort size, and lack of adequate 
statistical analyses. Trials in larger cohorts, with new, 
standardized analytical methodologies, including next-
generation sequencing, are warranted.
CONCLUSIONS AND FUTURE 
PERSPECTIVES
Several progresses have been made in the chemo-
therapeutic treatment of metastatic pancreatic cancer 
in these last few years, but these improvements are 
still mostly incremental, without major impact on the 
grim prognosis of these patients. 
Despite the substantially improved knowledge 
about basic pancreatic cancer biology and the recruit-
ment of hundreds of patients in many clinical trials, 
novel targeted therapies for angiogenic targets and 
tyrosine kinase have shown poor results. However, 
most of these trials did not evaluate predictive 
markers, which are essential to guide patient selection 
with biological agents. Moreover, most translational 
studies on candidate biomarkers, such as hENT1, TS 
and SPARC, showed controversial results. The major 
limitations of these studies should be overcome by 
prospective clinical trials, using standardized analytical 
methodologies, in which a direct comparison is 
performed between patient treatments selected on 
the basis of standard criteria vs treatment selection 
suggested by tumor characteristics. 
Other limitations arise from the intra-tumor 
heterogeneity and other complex epigenetic factors, 
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such as miRNA, which might foster tumor adaptation 
and therapeutic failure. Therefore, studies on miRNA 
may clarify the role of several signaling pathways in 
drug resistance and identify stronger biomarkers or 
new potential targets. 
Moreover, to evaluate the heterogeneity and 
possible evolution of cancer cells the future clinical 
trials should include multiple and repeated biopsies 
of the single tumor, and/or novel liquid biopsies. Most 
recent studies have showed promising results for 
liquid biopsy-based molecular diagnostics in patients 
with several types of cancer, including pancreatic 
cancer[137,138]. In particular, by investigating circulating 
metabolites in plasma from 4 cohorts of pancreatic 
cancer patients and matching controls, elevated plasma 
levels of branched-chain amino acids (BCAAs) have 
been associated with a greater than two-fold increa-
sed risk of pancreatic carcinogenesis. Remarkably, 
plasma BCAAs were elevated in mice with early-stage 
pancreatic cancers driven by mutant Kras expression 
but not in mice with KRAS-driven tumors in other 
tissues, suggesting that increased whole-body protein 
breakdown is a specific event that accompanies early 
stage development of pancreatic cancer[138].
Early detection of a druggable biomarker in the 
natural history of the single patient can indeed be 
crucial, considering the rapidly progressing disease 
and the sudden deterioration of general conditions that 
commonly characterize the subset of pancreatic cancer 
patients. The individualized molecular pancreatic 
cancer trial is a good example of a trial aimed at 
improving outcome of patients with recurrence or 
metastases pancreatic cancer using molecular analysis 
on tumor specimens to guide treatment decision. 
This trial was designed as a randomized phase Ⅱ 
trial in 2010, before the “FOLFIRINOX/nab-paclitaxel-
gemcitabine era”. Therefore, the patients were 
randomized to receive chemotherapy with gemcitabine 
or personalized treatment depending on the genetic 
biomarker expressed: patients with amplification of 
HER-2, absence of KRAS mutation or patients with 
mutation in DNA damage repair genes (BRCA1 and 
2-ATM-PALB2) were eligible for personalized therapy. 
This trial showed the feasibility of collecting and 
analyzing samples for candidate molecular targets in 
real-time and prompt future translational studies with 
similar design[139,140]. 
Many ongoing trials are evaluating the combination 
of new agents within both “FOLFIRINOX-based” and 
“nab-paclitaxel-based” therapies, as extensively 
reviewed by Vaccaro and collaborators[141]. An interesting 
approach is the combination with immunotherapy, and 
a recent study phase Ib study showed promising results 
for FOLFIRINOX in combination with a CCR2 inhibitor 
PF-04136309, which will be further investigated in a 
phase Ⅱ randomized trial. The rationale of this study is 
based on the fact that the CCL2-CCR2 chemokine axis 
is involved in recruiting tumor-associated macrophages 
and in the construction of the immunosuppressive 
microenvironment of pancreatic cancer[142]. Hopefully, 
within these trials, as well as in other ongoing and future 
clinical protocols, the availability of new technologies 
for appropriate parallel translational studies will identify 
solid predictive biomarkers that in turn can be used 
to select the most appropriate pharmacological agent 
for personalization of the treatment (i.e., precision 
medicine). For this goal both the careful collection of 
tissue samples, and the coordinated multidisciplinary 
work of surgeons, radiologists, gastroenterologists, 
oncologists and scientists, will be crucial to evaluate the 
best experimental therapeutic options for each given 
patient, and should therefore enter as soon as possible 
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Table 3  miRNA candidates correlated to anticancer treatment resistance to the drugs in the FOLFIRINOX and nab-paclitaxel/
gemcitabine regimens in tissues and cells from solid tumors
Drug miRNA Expression/polymorphism Tumor type Ref.
5-FU miR-21 Overexpression Pancreatic cancer Donahue et al[126], J Surg Oncol 2014
5-FU and irinotecan pri-miR26a-1 rs7372209 polymorphism Colorectal cancer Boni et al[132], Pharmacogenomics J 2011
5-FU and oxaliplatin miR-106a, miR-484, 
miR-130b
Overexpression Colorectal cancer Kjersem et al[143], Mol Oncol 2014
5-FU, paclitaxel and oxaliplatin miR-27a Overexpression Gastric cancer Huang et al[135], J Cell Biochem 2014
5-FU, capecitabine and oxaliplatin miR-625-3p, 
miR-181b, miR-27b
Overexpression Colorectal cancer Rasmussen et al[133], Mol Oncol 2013
Irinotecan and cetuximab miR-345 Overexpression Colorectal cancer Schou et al[144], PLoS One 2014
Oxaliplatin miR-203 Overexpression Colorectal cancer Zhou et al[145], Mol Oncol 2014
Carboplatin and paclitaxel ± sorafenib miR-659-3p Downregulation Melanoma Villaruz et al[136], Clin Epigenetics 2015
Paclitaxel miR-200c Downregulation Ovarian and 
endometrial cancer
Cochrane et al[146], Mol Cancer Ther 2009
Paclitaxel miR-145 Downregulation Ovarian cancer Zhu et al[147], Int J Cancer 2014
Paclitaxel miR-17-5p Downregulation Lung cancer Aggarwal et al[148], Planta Med 2008
Gemcitabine miR-21 Overexpression Pancreatic cancer Hwang et al[127], PLoS One 2010
Giovannetti et al[128], Cancer Res 2010
Caponi et al[129], Ann Oncol 2013
Gemcitabine miR-21, miR-23a, 
miR-27a
Overexpression Pancreatic cancer Frampton et al[131], Gastroenterology 2014
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